Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model

PR Newswire May 13, 2020

Lipocine Announces First Quarter 2020 Financial and Operational Results

PR Newswire May 7, 2020

FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial

PR Newswire May 5, 2020

U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition

PR Newswire April 17, 2020

Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO

PR Newswire April 9, 2020

Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

PR Newswire March 26, 2020

Lipocine Announces 2019 Year End Financial and Operational Results

PR Newswire March 13, 2020

Lipocine Announces TLANDO(TM) PDUFA Date of August 28, 2020

PR Newswire March 4, 2020

Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants

PR Newswire February 27, 2020

Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market

PR Newswire February 25, 2020

Lipocine Announces Regulatory Path Forward for TLANDO(TM) Resubmission

PR Newswire February 24, 2020

Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics

PR Newswire February 11, 2020

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire January 14, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lipocine Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA January 14, 2020

LPCN FINAL DEADLINE TODAY: Rosen, a Leading Law Firm, Reminds Lipocine Inc. Investors of Important January 14th Deadline in Securities Class Action - LPCN

GlobeNewswire January 14, 2020

TUESDAY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Lipocine, Inc. and Encourages Investors to Contact the Firm

GlobeNewswire January 13, 2020

LPCN FINAL DEADLING: ROSEN, A TOP FIRM, Reminds Lipocine Inc. Investors of Important January 14 Deadline in Securities Class Action - LPCN

ACCESSWIRE IA January 13, 2020

FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Lipocine Inc.

Business Wire January 13, 2020

FINAL DEADLINE ALERT - Lipocine Inc. (LPCN) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: January 14, 2020

ACCESSWIRE IA January 13, 2020

TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire January 13, 2020